- Home
- MLTX vs LXRX Comparison
MLTX vs LXRX Comparison
Compare MLTX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- LXRX
- Stock Information
- Founded
- MLTX 2021
- LXRX 1995
- Country
- MLTX Switzerland
- LXRX United States
- Employees
- MLTX N/A
- LXRX N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLTX Health Care
- LXRX Health Care
- Exchange
- MLTX Nasdaq
- LXRX Nasdaq
- Market Cap
- MLTX 535.3M
- LXRX 428.8M
- IPO Year
- MLTX N/A
- LXRX 2000
- Fundamental
- Price
- MLTX $9.40
- LXRX $1.52
- Analyst Decision
- MLTX Buy
- LXRX Buy
- Analyst Count
- MLTX 9
- LXRX 5
- Target Price
- MLTX $37.63
- LXRX $3.23
- AVG Volume (30 Days)
- MLTX 9.7M
- LXRX 2.6M
- Earning Date
- MLTX 11-06-2025
- LXRX 11-11-2025
- Dividend Yield
- MLTX N/A
- LXRX N/A
- EPS Growth
- MLTX N/A
- LXRX N/A
- EPS
- MLTX N/A
- LXRX N/A
- Revenue
- MLTX N/A
- LXRX $58,432,000.00
- Revenue This Year
- MLTX N/A
- LXRX $67.21
- Revenue Next Year
- MLTX N/A
- LXRX N/A
- P/E Ratio
- MLTX N/A
- LXRX N/A
- Revenue Growth
- MLTX N/A
- LXRX 1504.83
- 52 Week Low
- MLTX $5.95
- LXRX $0.28
- 52 Week High
- MLTX $62.75
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- MLTX 23.29
- LXRX 70.28
- Support Level
- MLTX $6.56
- LXRX $1.28
- Resistance Level
- MLTX $7.48
- LXRX $1.42
- Average True Range (ATR)
- MLTX 2.22
- LXRX 0.10
- MACD
- MLTX -4.37
- LXRX 0.02
- Stochastic Oscillator
- MLTX 6.07
- LXRX 81.00
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.